Plain-English translation of NCT06735326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new type of cancer medication, either alone or combined with another drug called , to see how well it shrinks advanced ovarian cancer before surgery. The study will compare these new treatments to standard chemotherapy to find out which approach works best and is safest for patients with a BRCA gene mutation.
Many patients with advanced ovarian cancer cannot have surgery right away or may not be healthy enough for it. This medication is designed to shrink the tumor first, making surgery safer and more effective, and may offer a better treatment option than traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the new medication alone, the new medication combined with , or standard chemotherapy before your surgery. The medication phase lasts about 8 weeks, followed by surgery and possibly additional chemotherapy. You will have regular clinic visits, blood tests, and imaging scans to check how well the treatment is working, and you will complete surveys about how the treatment affects your quality of life.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China